img

Global Biologics Monoclonal Antibodies Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Biologics Monoclonal Antibodies Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
Biologics Monoclonal Antibodies Drug report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Biologics Monoclonal Antibodies Drug market is projected to reach US$ 470320 million in 2029, increasing from US$ 212750 million in 2022, with the CAGR of 12.0% during the period of 2024 to 2029. Demand from Cancer and Autoimmune Disease are the major drivers for the industry.
The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biologics Monoclonal Antibodies Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Eli Lilly
Novartis
Merck
Biogen
Sobi
Innovent Biologics
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other

Segment by Application


Cancer
Autoimmune Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Biologics Monoclonal Antibodies Drug market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Biologics Monoclonal Antibodies Drug introduction, etc. Biologics Monoclonal Antibodies Drug Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Biologics Monoclonal Antibodies Drug market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Biologics Monoclonal Antibodies Drug
1.1 Biologics Monoclonal Antibodies Drug Market Overview
1.1.1 Biologics Monoclonal Antibodies Drug Product Scope
1.1.2 Biologics Monoclonal Antibodies Drug Market Status and Outlook
1.2 Global Biologics Monoclonal Antibodies Drug Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Biologics Monoclonal Antibodies Drug Market Size by Region (2018-2029)
1.4 Global Biologics Monoclonal Antibodies Drug Historic Market Size by Region (2018-2024)
1.5 Global Biologics Monoclonal Antibodies Drug Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
1.6.1 North America Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
1.6.2 Europe Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
1.6.3 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
1.6.4 Latin America Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
1.6.5 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size (2018-2029)
2 Biologics Monoclonal Antibodies Drug Market by Type
2.1 Introduction
2.1.1 Infliximab
2.1.2 Rituximab
2.1.3 Trastuzumab
2.1.4 Adalimumab
2.1.5 Other
2.2 Global Biologics Monoclonal Antibodies Drug Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Biologics Monoclonal Antibodies Drug Historic Market Size by Type (2018-2024)
2.2.2 Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Biologics Monoclonal Antibodies Drug Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Biologics Monoclonal Antibodies Drug Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Biologics Monoclonal Antibodies Drug Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue Breakdown by Type (2018-2029)
3 Biologics Monoclonal Antibodies Drug Market Overview by Application
3.1 Introduction
3.1.1 Cancer
3.1.2 Autoimmune Disease
3.1.3 Other
3.2 Global Biologics Monoclonal Antibodies Drug Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Biologics Monoclonal Antibodies Drug Historic Market Size by Application (2018-2024)
3.2.2 Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Biologics Monoclonal Antibodies Drug Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Biologics Monoclonal Antibodies Drug Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Biologics Monoclonal Antibodies Drug Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue Breakdown by Application (2018-2029)
4 Biologics Monoclonal Antibodies Drug Competition Analysis by Players
4.1 Global Biologics Monoclonal Antibodies Drug Market Size by Players (2018-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biologics Monoclonal Antibodies Drug as of 2022)
4.3 Date of Key Players Enter into Biologics Monoclonal Antibodies Drug Market
4.4 Global Top Players Biologics Monoclonal Antibodies Drug Headquarters and Area Served
4.5 Key Players Biologics Monoclonal Antibodies Drug Product Solution and Service
4.6 Competitive Status
4.6.1 Biologics Monoclonal Antibodies Drug Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.1.4 Roche Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.1.5 Roche Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.2.4 Amgen Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.2.5 Amgen Recent Developments
5.3 AbbVie
5.3.1 AbbVie Profile
5.3.2 AbbVie Main Business
5.3.3 AbbVie Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.3.4 AbbVie Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.4.4 Sanofi Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.4.5 Sanofi Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.5.2 Johnson & Johnson Main Business
5.5.3 Johnson & Johnson Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.5.4 Johnson & Johnson Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.5.5 Johnson & Johnson Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.6.4 Pfizer Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.6.5 Pfizer Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.7.4 Eli Lilly Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.7.5 Eli Lilly Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.8.4 Novartis Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.8.5 Novartis Recent Developments
5.9 Merck
5.9.1 Merck Profile
5.9.2 Merck Main Business
5.9.3 Merck Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.9.4 Merck Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.9.5 Merck Recent Developments
5.10 Biogen
5.10.1 Biogen Profile
5.10.2 Biogen Main Business
5.10.3 Biogen Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.10.4 Biogen Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.10.5 Biogen Recent Developments
5.11 Sobi
5.11.1 Sobi Profile
5.11.2 Sobi Main Business
5.11.3 Sobi Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.11.4 Sobi Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.11.5 Sobi Recent Developments
5.12 Innovent Biologics
5.12.1 Innovent Biologics Profile
5.12.2 Innovent Biologics Main Business
5.12.3 Innovent Biologics Biologics Monoclonal Antibodies Drug Products, Services and Solutions
5.12.4 Innovent Biologics Biologics Monoclonal Antibodies Drug Revenue (US$ Million) & (2018-2024)
5.12.5 Innovent Biologics Recent Developments
6 North America
6.1 North America Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Biologics Monoclonal Antibodies Drug Market Dynamics
11.1 Biologics Monoclonal Antibodies Drug Industry Trends
11.2 Biologics Monoclonal Antibodies Drug Market Drivers
11.3 Biologics Monoclonal Antibodies Drug Market Challenges
11.4 Biologics Monoclonal Antibodies Drug Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Biologics Monoclonal Antibodies Drug Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
Table 2. Global Biologics Monoclonal Antibodies Drug Market Size by Region (2018-2024) & (US$ Million)
Table 3. Global Biologics Monoclonal Antibodies Drug Market Size Share by Region (2018-2024)
Table 4. Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 5. Global Biologics Monoclonal Antibodies Drug Forecasted Market Size Share by Region (2024-2029)
Table 6. Global Biologics Monoclonal Antibodies Drug Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
Table 7. Global Biologics Monoclonal Antibodies Drug Market Size by Type (2018-2024) & (US$ Million)
Table 8. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2018-2024)
Table 9. Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 10. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2024-2029)
Table 11. North America Biologics Monoclonal Antibodies Drug Revenue by Type (2018-2024) & (US$ Million)
Table 12. North America Biologics Monoclonal Antibodies Drug Revenue by Type (2024-2029) & (US$ Million)
Table 13. Europe Biologics Monoclonal Antibodies Drug Revenue by Type (2018-2024) & (US$ Million)
Table 14. Europe Biologics Monoclonal Antibodies Drug Revenue by Type (2024-2029) & (US$ Million)
Table 15. Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue by Type (2018-2024) & (US$ Million)
Table 16. Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue by Type (2024-2029) & (US$ Million)
Table 17. Latin America Biologics Monoclonal Antibodies Drug Revenue by Type (2018-2024) & (US$ Million)
Table 18. Latin America Biologics Monoclonal Antibodies Drug Revenue by Type (2024-2029) & (US$ Million)
Table 19. Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue by Type (2018-2024) & (US$ Million)
Table 20. Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue by Type (2024-2029) & (US$ Million)
Table 21. Global Biologics Monoclonal Antibodies Drug Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
Table 22. Global Biologics Monoclonal Antibodies Drug Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2018-2024)
Table 24. Global Biologics Monoclonal Antibodies Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 25. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2024-2029)
Table 26. North America Biologics Monoclonal Antibodies Drug Revenue by Application (2018-2024) & (US$ Million)
Table 27. North America Biologics Monoclonal Antibodies Drug Revenue by Application (2024-2029) & (US$ Million)
Table 28. Europe Biologics Monoclonal Antibodies Drug Revenue by Application (2018-2024) & (US$ Million)
Table 29. Europe Biologics Monoclonal Antibodies Drug Revenue by Application (2024-2029) & (US$ Million)
Table 30. Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue by Application (2018-2024) & (US$ Million)
Table 31. Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue by Application (2024-2029) & (US$ Million)
Table 32. Latin America Biologics Monoclonal Antibodies Drug Revenue by Application (2018-2024) & (US$ Million)
Table 33. Latin America Biologics Monoclonal Antibodies Drug Revenue by Application (2024-2029) & (US$ Million)
Table 34. Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue by Application (2018-2024) & (US$ Million)
Table 35. Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue by Application (2024-2029) & (US$ Million)
Table 36. Global Biologics Monoclonal Antibodies Drug Revenue (US$ Million) by Players (2018-2024)
Table 37. Global Biologics Monoclonal Antibodies Drug Revenue Market Share by Players (2018-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biologics Monoclonal Antibodies Drug as of 2022)
Table 39. Date of Key Players Enter into Biologics Monoclonal Antibodies Drug Market
Table 40. Global Biologics Monoclonal Antibodies Drug Key Players Headquarters and Area Served
Table 41. Biologics Monoclonal Antibodies Drug Product Solution and Service
Table 42. Global Biologics Monoclonal Antibodies Drug Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Roche Basic Information List
Table 45. Roche Description and Business Overview
Table 46. Roche Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 47. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Roche (2018-2024)
Table 48. Roche Recent Developments
Table 49. Amgen Basic Information List
Table 50. Amgen Description and Business Overview
Table 51. Amgen Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 52. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Amgen (2018-2024)
Table 53. Amgen Recent Developments
Table 54. AbbVie Basic Information List
Table 55. AbbVie Description and Business Overview
Table 56. AbbVie Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 57. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of AbbVie (2018-2024)
Table 58. AbbVie Recent Developments
Table 59. Sanofi Basic Information List
Table 60. Sanofi Description and Business Overview
Table 61. Sanofi Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 62. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Sanofi (2018-2024)
Table 63. Sanofi Recent Developments
Table 64. Johnson & Johnson Basic Information List
Table 65. Johnson & Johnson Description and Business Overview
Table 66. Johnson & Johnson Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 67. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Johnson & Johnson (2018-2024)
Table 68. Johnson & Johnson Recent Developments
Table 69. Pfizer Basic Information List
Table 70. Pfizer Description and Business Overview
Table 71. Pfizer Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 72. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Pfizer (2018-2024)
Table 73. Pfizer Recent Developments
Table 74. Eli Lilly Basic Information List
Table 75. Eli Lilly Description and Business Overview
Table 76. Eli Lilly Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 77. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Eli Lilly (2018-2024)
Table 78. Eli Lilly Recent Developments
Table 79. Novartis Basic Information List
Table 80. Novartis Description and Business Overview
Table 81. Novartis Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 82. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Novartis (2018-2024)
Table 83. Novartis Recent Developments
Table 84. Merck Basic Information List
Table 85. Merck Description and Business Overview
Table 86. Merck Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 87. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Merck (2018-2024)
Table 88. Merck Recent Developments
Table 89. Biogen Basic Information List
Table 90. Biogen Description and Business Overview
Table 91. Biogen Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 92. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Biogen (2018-2024)
Table 93. Biogen Recent Developments
Table 94. Sobi Basic Information List
Table 95. Sobi Description and Business Overview
Table 96. Sobi Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 97. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Sobi (2018-2024)
Table 98. Sobi Recent Developments
Table 99. Innovent Biologics Basic Information List
Table 100. Innovent Biologics Description and Business Overview
Table 101. Innovent Biologics Biologics Monoclonal Antibodies Drug Products, Services and Solutions
Table 102. Revenue (US$ Million) in Biologics Monoclonal Antibodies Drug Business of Innovent Biologics (2018-2024)
Table 103. Innovent Biologics Recent Developments
Table 104. North America Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2024) & (US$ Million)
Table 105. North America Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029) & (US$ Million)
Table 106. Europe Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2024) & (US$ Million)
Table 107. Europe Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029) & (US$ Million)
Table 108. Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 109. Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Region (2018-2024) & (US$ Million)
Table 110. Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size by Region (2024-2029) & (US$ Million)
Table 111. Asia-Pacific Biologics Monoclonal Antibodies Drug Market Share by Region (2018-2024)
Table 112. Asia-Pacific Biologics Monoclonal Antibodies Drug Market Share by Region (2024-2029)
Table 113. Latin America Biologics Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 114. Latin America Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2024) & (US$ Million)
Table 115. Latin America Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029) & (US$ Million)
Table 116. Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 117. Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country (2018-2024) & (US$ Million)
Table 118. Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size by Country (2024-2029) & (US$ Million)
Table 119. Biologics Monoclonal Antibodies Drug Market Trends
Table 120. Biologics Monoclonal Antibodies Drug Market Drivers
Table 121. Biologics Monoclonal Antibodies Drug Market Challenges
Table 122. Biologics Monoclonal Antibodies Drug Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Biologics Monoclonal Antibodies Drug Market Size Year-over-Year 2018-2029 & (US$ Million)
Figure 2. Global Biologics Monoclonal Antibodies Drug Market Size (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Biologics Monoclonal Antibodies Drug Market Share by Regions: 2022 VS 2029
Figure 4. Global Biologics Monoclonal Antibodies Drug Forecasted Market Size Share by Region (2024-2029)
Figure 5. North America Biologics Monoclonal Antibodies Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 6. Europe Biologics Monoclonal Antibodies Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 7. Asia-Pacific Biologics Monoclonal Antibodies Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 8. Latin America Biologics Monoclonal Antibodies Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 9. Middle East & Africa Biologics Monoclonal Antibodies Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 10. Product Picture of Infliximab
Figure 11. Global Infliximab Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 12. Product Picture of Rituximab
Figure 13. Global Rituximab Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 14. Product Picture of Trastuzumab
Figure 15. Global Trastuzumab Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 16. Product Picture of Adalimumab
Figure 17. Global Adalimumab Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 18. Product Picture of Other
Figure 19. Global Other Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 20. Global Biologics Monoclonal Antibodies Drug Market Size Share by Type: 2022 & 2029
Figure 21. North America Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2018-2029)
Figure 22. Europe Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2018-2029)
Figure 23. Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2018-2029)
Figure 24. Latin America Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2018-2029)
Figure 25. Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue Market Share by Type (2018-2029)
Figure 26. Cancer Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 27. Autoimmune Disease Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 28. Other Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 29. Global Biologics Monoclonal Antibodies Drug Market Size Share by Application: 2022 & 2029
Figure 30. North America Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2018-2029)
Figure 31. Europe Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2018-2029)
Figure 32. Asia-Pacific Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2018-2029)
Figure 33. Latin America Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2018-2029)
Figure 34. Middle East and Africa Biologics Monoclonal Antibodies Drug Revenue Market Share by Application (2018-2029)
Figure 35. Biologics Monoclonal Antibodies Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 36. Global Top 5 and Top 10 Players Biologics Monoclonal Antibodies Drug Market Share in 2022
Figure 37. North America Biologics Monoclonal Antibodies Drug Market Share by Country (2018-2029)
Figure 38. United States Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 39. Canada Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 40. Germany Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 41. France Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 42. U.K. Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 43. Italy Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 44. Russia Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 45. Nordic Countries Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 46. Asia-Pacific Biologics Monoclonal Antibodies Drug Market Share by Region (2018-2029)
Figure 47. China Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 48. Japan Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 49. South Korea Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 50. Southeast Asia Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 51. India Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 52. Australia Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 53. Latin America Biologics Monoclonal Antibodies Drug Market Share by Country (2018-2029)
Figure 54. Mexico Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 55. Brazil Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 56. Middle East & Africa Biologics Monoclonal Antibodies Drug Market Share by Country (2018-2029)
Figure 57. Turkey Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 58. Saudi Arabia Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 59. UAE Biologics Monoclonal Antibodies Drug Market Size (2018-2029) & (US$ Million)
Figure 60. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries